Physicians wanted to improve outcomes for patients battling diseases including neuroblastoma and medulloblastoma, but this required the development of new treatments.
A team of oncologists, pediatricians, geneticists and patient families established the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) to treat patients using precision medicine.
• Achieves remission in patients previously deemed incurable
• Improves long-term health outcomes for cancer survivors
• Increases scientific understanding of cancer and genes
• Gathers big data that can facilitate medical breakthroughs
• Shows organizations how to implement precision medicine